Treatment Settings

For Immediate Release: May 23, 2023 Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD)...

For Immediate Release: May 24, 2023 Today, the U.S. Food and Drug Administration (FDA) approved the extended-release Brixadi (buprenorphine) subcutaneous (for use under the skin) injection to treat moderate to severe opioid use disorder...

Stories about substance use and addiction can be among the thorniest that health and science reporters encounter. This topic carries a long history of marginalizing the people most directly affected. In addition, deeply ingrained societal misconceptions about substance use make it difficult to separate fact from fiction

Abstract Importance The use of cannabis as a medicine is becoming increasingly prevalent. Given the diverse range of conditions being treated with medical cannabis, as well as the vast array of products and dose forms available, clinical...

Abstract Background SMART (Self-Management and Recovery Training) Recovery is a mutual-aid program informed by cognitive behaviour therapy and motivational interviewing that provides support for a range of addictive behaviours. SMART...

Presented by Richard Rawson, PhD, Emeritus Professor in the Department of Psychiatry and Biobehavioral Science, UCLA School of Medicine and a Research Professor at the University of Vermont, this presentation provided an overview of the...

ISSUP Kenya present their Webinar on Insights from Positive Psychology and Psychology of Religion as applied to treatment and recovery from addiction.

The UNODC Regional Office for Central Asia (ROCA) together with the UNODC Prevention, Treatment and Rehabilitation Section (PTRS) organized a study tour for high-level representatives, including senior officials, policymakers and substance...